| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | PIR121 |
| WB Predicted band size | 148 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CYFIP2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CYFIP2抗体的3篇文献示例，格式为文献名称、作者及简要摘要内容：
---
1. **"CYFIP2 regulates neurodevelopmental pathways associated with autism spectrum disorder"**
*Authors: Smith J, Doe A, Lee S.*
摘要：研究利用CYFIP2特异性抗体，通过免疫印迹和免疫组化分析，发现CYFIP2在神经元突触形成中的作用，并揭示其表达异常与自闭症谱系障碍的潜在关联。
2. **"Cytoplasmic FMR1-interacting protein 2 (CYFIP2) modulates cancer cell invasion via Rac1 signaling"**
*Authors: Zhang L, Wang Y, Chen H.*
摘要：通过CYFIP2抗体进行蛋白质互作实验，证实CYFIP2通过调控Rac1信号通路影响肿瘤细胞迁移，为癌症治疗提供新靶点。
3. **"A novel role of CYFIP2 in mitochondrial dynamics and oxidative stress response"**
*Authors: Kim T, Park M, Ito K.*
摘要：使用CYFIP2抗体进行免疫荧光和流式细胞术，发现CYFIP2参与线粒体形态调控，并在氧化应激条件下保护细胞免受损伤。
---
**注**：以上文献信息为示例，实际研究中建议通过PubMed或Google Scholar以关键词“CYFIP2 antibody”或“CYFIP2 function”检索具体文献，并核实实验细节及抗体来源(如Abcam、Santa Cruz等厂商编号)。
The CYFIP2 (Cytoplasmic FMR1-Interacting Protein 2) antibody is a key tool for studying the role of CYFIP2. a protein involved in neuronal development, synaptic plasticity, and cellular signaling. CYFIP2 is part of the WAVE regulatory complex (WRC), which regulates actin cytoskeleton dynamics critical for cell motility, morphology, and synaptic function. It also interacts with FMRP (Fragile X Mental Retardation Protein), linking it to mRNA translation regulation and neurodevelopmental disorders like autism and Fragile X syndrome.
This antibody is widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect CYFIP2 expression and localization in tissues or cultured cells. Researchers employ it to investigate CYFIP2's involvement in neurological diseases, including Alzheimer’s disease, intellectual disabilities, and epilepsy, as altered CYFIP2 levels correlate with synaptic dysfunction. Specificity is validated through knockout (KO) controls or siRNA knockdown to ensure minimal cross-reactivity with its homolog CYFIP1.
Commercially available CYFIP2 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes (e.g., N-terminal or C-terminal regions). Proper validation ensures reliability in both quantitative and qualitative analyses, aiding studies on CYFIP2’s regulatory mechanisms in health and disease. Its application continues to advance understanding of neuropathologies and potential therapeutic targets.
×
